End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.74 CNY | +3.88% | +4.12% | -1.81% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.55 for the 2024 fiscal year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.81% | 1.81B | C- | ||
-22.12% | 12.04B | B | ||
-24.76% | 6.52B | B | ||
+15.41% | 6.44B | C | ||
-10.11% | 6.15B | C+ | ||
-2.48% | 4.63B | D- | ||
+60.00% | 4.62B | C | ||
-6.67% | 3.93B | B | ||
-10.60% | 3.49B | C- | ||
-6.53% | 3.05B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002727 Stock
- Ratings Yixintang Pharmaceutical Group Co., Ltd.